[13C]-galactose breath test: Correlation with liver fibrosis in chronic hepatitis C

European Journal of Clinical Investigation

Volumn 29, Issue 7, 1999, Pages 624-629

  Mion, F ^a   Rousseau, M ^a   Scoazec, J Y ^a   Berger, F ^a   Minaire, Y ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Human; Liver function test; Stable isotopes

Indexed keywords

CARBON 13; GALACTOSE; CARBON; CARBON DIOXIDE; DIAGNOSTIC AGENT;

ADULT; ARTICLE; BREATH ANALYSIS; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; BIOPSY; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; BIOPSY; BREATH TESTS; CARBON DIOXIDE; CARBON ISOTOPES; FEMALE; GALACTOSE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 0032588192     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00512.x     Document Type: Article

References (27)

1. 1 Tygstrup N. The galactose elimination capacity in control subjects and in patients with cirrhosis of the liver. Acta Med Scand 1964;175:281-9.
2. 2 Reichen J, Widmer T, Cotting J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: a comparison with the Mayo model. Hepatology 1991;14:504-10.
3. 3 Merckel C, Marchesini G, Fabri A, et al. The course of galactose elimination capacity in patients with alcoholic cirrhosis: possible use as a surrogate marker for death. Hepatology 1996;24:820-3.
4. 4 Lotterer E, Hogel J, Gaus W, Fleig WE, Bircher J. Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: a retrospective feasibility study. Hepatology 1997;26:1426-33.
5. 5 Myren J, Kierulf P. The intravenous galactose test as indicator of the extent of fibrosis in patients with cirrhosis of the liver. Scand J Gastroenterol 1969;4:453-6.
6. 6 Lindskov J. The quantitative liver function as measured by the galactose elimination capacity. Acta Med Scand 1982;212:295-302.
7. 7 Testa R, Campo N, Caglieris S, et al. Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis. Hepatogastroenterology 1998;45:154-9.
8. 13C-galactose breath test: comparison with galactose elimination capacity to measure liver function. Gastroenterology 1995;108:A1124.
9. 9 Parvaz P, Guichard E, Chevallier P, et al. description of a highly sensitive method for clinical detection of viral RNA. J Virol Methods 1994;47:83-94.
10. 10 The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
11. 11 Henderson JM, Kutner MH, Bain RP. First-order clearance of plasma galactose: the effect of liver disease. Gastroenterology 1982;83:1090-6.
12. 13C-galactose breath tests. Life Sci 1994;54:2093-8.
13. 13 Guilluy R, Billion-Rey F, Pachiaudi C, et al. On-line purification and carbon-13 isotopic analysis of carbon dioxide in breath: evaluation of on-line gas chromatography-isotope ratio mass spectrometry. Analyt Chim Acta 1992;259:193-202.
14. 2 breath tests. Am J Clin Nutr 1980;33:2375-85.
15. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992;52:170-80.
16. 16 de Verdier CH, Hjelm M. A galactose-oxidase method for the determination of galactose in blood plasma. Clin Chim Acta 1962;7:742-4.
17. 17 Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
18. 14C-D-galactose breath test for evaluation of liver function in patients with chronic liver disease. Digestion 1978;17:410-8.
19. 19 Grimm L, Bircher J, Preisig R. The galactose breath test. Modification of the method and comparison with galactose elimination capacity and plasma disappearance of bromsulphatein. Z Gastroenterol 1980;18:45-56.
20. 20 Shreeve WW. Impaired oxidation of carbon-labeled galactose by alcoholic or diabetic liver in vivo. Nuklearmedizin 1987;26:159-66.
21. 21 Fabbri A, Bianchi G, Brizi M, Zoli M, Marchesini G. Uncertainty in liver function assessment on the basis of single-point galactose concentration. Digestion 1997;58:379-83.
22. 22 Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
23. 23 Dienstag JL. The natural history of chronic hepatitis C and what we should do about it. Gastroenterology 1997;112:651-5.
24. 24 Gross JB, Reichen J, Zeltner TB, Zimmermann A. The evolution of changes in quantitative liver function tests in a rat model of biliary cirrhosis: correlation with morphometric measurement of hepatocyte mass. Hepatology 1987;7:457-63.
25. 25 Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
26. 26 Isselbacher KJ, Krane SM. Studies on the mechanism of the inhibition of galactose oxidation by ethanol. J Biol Chem 1961;236:2394-8.
27. 27 Mion F, Géloën A, Minaire Y. Effects of ethanol and diabetes on galactose oxidative metabolism and elimination in rats. Can J Physiol Pharmacol 1999 (in press).